DK0888452T3 - Human CYR61, et ekstracellulært matrix-signalmolekyle - Google Patents

Human CYR61, et ekstracellulært matrix-signalmolekyle

Info

Publication number
DK0888452T3
DK0888452T3 DK97916018T DK97916018T DK0888452T3 DK 0888452 T3 DK0888452 T3 DK 0888452T3 DK 97916018 T DK97916018 T DK 97916018T DK 97916018 T DK97916018 T DK 97916018T DK 0888452 T3 DK0888452 T3 DK 0888452T3
Authority
DK
Denmark
Prior art keywords
ecm signalling
signalling molecules
mammalian ecm
methods
mammalian
Prior art date
Application number
DK97916018T
Other languages
English (en)
Inventor
Lester F Lau
Original Assignee
Munin Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Munin Corp filed Critical Munin Corp
Application granted granted Critical
Publication of DK0888452T3 publication Critical patent/DK0888452T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK97916018T 1996-03-15 1997-03-14 Human CYR61, et ekstracellulært matrix-signalmolekyle DK0888452T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1395896P 1996-03-15 1996-03-15

Publications (1)

Publication Number Publication Date
DK0888452T3 true DK0888452T3 (da) 2004-06-14

Family

ID=21762734

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97916018T DK0888452T3 (da) 1996-03-15 1997-03-14 Human CYR61, et ekstracellulært matrix-signalmolekyle

Country Status (11)

Country Link
US (3) US6413735B1 (da)
EP (1) EP0888452B1 (da)
JP (1) JP4307552B2 (da)
CN (1) CN1263852C (da)
AT (1) ATE259419T1 (da)
AU (1) AU733382B2 (da)
CA (1) CA2248549A1 (da)
DE (1) DE69727558T2 (da)
DK (1) DK0888452T3 (da)
HK (1) HK1018707A1 (da)
WO (1) WO1997033995A2 (da)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1217067A2 (en) 1994-07-12 2002-06-26 Human Genome Sciences, Inc. Connective tissue growth factor-2
US7026299B2 (en) 1994-07-12 2006-04-11 Human Genome Sciences, Inc. Connective tissue growth factor-2
CN1263852C (zh) 1996-03-15 2006-07-12 穆尼恩公司 胞外基质信号分子
US7521540B2 (en) 1996-03-15 2009-04-21 Munin Corporation CYR61 compositions and methods
US6562618B1 (en) * 1997-12-25 2003-05-13 Japan Tobacco, Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
GB2353282C (en) 1998-03-20 2013-02-27 State Queensland Primary Ind Control of gene expression
AU5301499A (en) 1998-08-20 2000-03-14 Chugai Seiyaku Kabushiki Kaisha Method for screening candidate compounds for drug against tumor
AU5807500A (en) 1999-07-14 2001-02-05 Novo Nordisk A/S Use of fviia or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
EP1626056B1 (en) * 1999-12-30 2012-03-28 President and Fellows of Harvard College Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or T cell subset activity by modulation of XBP-1 activity
EP1892250A3 (en) * 2000-01-31 2008-09-17 Munin Corporation CYR61 compositions and methods
CN1447819B (zh) * 2000-01-31 2011-06-22 妙甯公司 人cyr61
EP1263484B1 (en) * 2000-03-15 2007-05-16 OrbusNeich Medical, Inc. Coating which promotes endothelial cell adherence
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8460367B2 (en) 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
AU2001271365A1 (en) * 2000-06-21 2002-01-02 Wyeth Cyr61 as a target for treatment and diagnosis of breast cancer
CA2412124A1 (en) * 2000-07-11 2002-01-17 Haodong Li Connective tissue growth factor-2
TWI249519B (en) 2000-08-29 2006-02-21 Nobex Corp Immunoregulatory compounds and derivatives and methods of treating diseases therewith
US6991901B2 (en) 2001-01-11 2006-01-31 Curagen Corporation Proteins and nucleic acids encoding same
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
EP1572984B8 (en) 2002-12-16 2016-06-01 Technion Research & Development Foundation Ltd. Feeder-free, xeno-free culture system for human embryonic stem cells
EP1608970A4 (en) * 2003-03-31 2006-06-14 Munin Corp CCN3 COMPOSITIONS AND METHODS
JP2004315480A (ja) * 2003-04-21 2004-11-11 Yoshiyuki Kakehi 前立腺疾患治療用医薬組成物
CN1835763B (zh) * 2003-06-20 2011-04-20 妙甯公司 Ccn1组合物和方法
CA2530255C (en) 2003-06-27 2015-12-08 Ethicon, Incorporated Soft tissue repair and regeneration using postpartum-derived cells
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US8491883B2 (en) 2003-06-27 2013-07-23 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US7875272B2 (en) * 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
US8518390B2 (en) 2003-06-27 2013-08-27 Advanced Technologies And Regenerative Medicine, Llc Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
US20050177885A1 (en) * 2004-02-09 2005-08-11 Lau Lester F. CCN1 transgenic animals
US7932366B2 (en) 2004-07-07 2011-04-26 Biocon Limited Synthesis of azo bonded immunoregulatory compounds
JP5340599B2 (ja) 2004-12-23 2013-11-13 エシコン・インコーポレイテッド 臍帯組織由来産褥細胞ならびにその製造方法および使用方法
PT1835924E (pt) 2004-12-23 2013-11-19 Ethicon Inc Tratamento da doença de parkinson e desordens relacionadas usando células derivadas do pós-parto
US20070037186A1 (en) 2005-05-20 2007-02-15 Yuqiu Jiang Thyroid fine needle aspiration molecular assay
AU2006286149B2 (en) 2005-08-29 2012-09-13 Technion Research And Development Foundation Ltd. Media for culturing stem cells
AU2006325710B2 (en) 2005-12-16 2012-05-17 Ethicon, Inc. Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation
ES2391034T3 (es) 2005-12-19 2012-11-20 Ethicon, Inc. Expansión in vitro de células derivadas postparto en frascos rotatorios
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
DK2733203T3 (da) 2006-08-02 2019-02-04 Technion Res & Dev Foundation Fremgangsmåder til ekspansion af embryonale stamceller i en suspensionskultur
CA2701435C (en) 2007-10-05 2017-06-20 Ethicon, Inc. Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells
US8236538B2 (en) 2007-12-20 2012-08-07 Advanced Technologies And Regenerative Medicine, Llc Methods for sterilizing materials containing biologically active agents
PL2237789T3 (pl) * 2007-12-27 2017-07-31 DePuy Synthes Products, Inc. Leczenie zwyrodnienia krążka międzykręgowego z zastosowaniem komórek pochodzących z tkanki pępowinowej
US8227184B2 (en) * 2008-01-14 2012-07-24 President And Fellows Of Harvard College Methods for modulating de novo hepatic lipogenesis by modulating XBP-1 activity
CN101747435B (zh) * 2008-12-18 2013-06-19 上海市免疫学研究所 一种中和cyr61的单克隆抗体(杂交瘤)及其应用
US10179900B2 (en) 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
ES2665883T3 (es) 2008-12-19 2018-04-30 DePuy Synthes Products, Inc. Tratamiento de enfermedades y trastornos pulmonares y pulmonares
BRPI1013409A2 (pt) 2009-03-26 2018-01-16 Advanced Tech And Regenerative Medicine Llc células de tecido de cordão umbilical humano como terapia para doença de alzheimer
TW201102086A (en) 2009-06-04 2011-01-16 Hoffmann La Roche Antibodies against human CCN1 and uses thereof
ES2779048T3 (es) 2009-11-12 2020-08-13 Technion Res & Dev Foundation Medios de cultivo, cultivos celulares y métodos de cultivo de células madre pluripotentes en un estado indiferenciado
WO2011066783A1 (zh) * 2009-12-04 2011-06-09 上海市免疫学研究所 抗Cyr61蛋白的单克隆抗体及其应用
WO2011107590A1 (en) 2010-03-04 2011-09-09 Wolfgang Poller Cnn1 (cyr61) for prevention and therapy of inflammatory disease
DE102010010288A1 (de) 2010-03-04 2011-09-08 Wolfgang Poller CCN1 zur Prävention und Therapie von entzündlichen Erkrankungen
US9347953B2 (en) * 2010-12-06 2016-05-24 Thd S.P.A. Method for the diagnosis of a carcinoma and uses thereof
US9956236B2 (en) 2011-02-07 2018-05-01 Cornell University Methods for increasing immune responses using agents that directly bind to and activate IRE-1
PL2794854T3 (pl) 2011-12-23 2018-12-31 DePuy Synthes Products, Inc. Wykrywanie ludzkich komórek pochodzących z tkanki pępowinowej
WO2013134774A1 (en) 2012-03-09 2013-09-12 Cornell University Modulation of breast cancer growth by modulation of xbp1 activity
CN105263529B (zh) 2013-04-12 2021-08-06 芒果基因制药公司 用于在脊椎动物个体中促进支架生物功能和伤口愈合的治疗性病毒微粒
WO2015013875A1 (zh) * 2013-07-30 2015-02-05 杭州微基质生物科技有限公司 一种全能干细胞培养方法
DK3049521T3 (da) 2013-09-25 2019-04-23 Univ Cornell Forbindelser til inducering af antitumorimmunitet og fremgangsmåder dertil
CN105396136B (zh) * 2015-11-23 2018-10-30 上海交通大学医学院附属第九人民医院 CCN1（Cyr61）在治疗皮肤损伤及皮肤萎缩相关疾病中的应用
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
CN110938128B (zh) * 2019-11-08 2021-07-13 上海交通大学 一种生物活性多肽pkcpkcdkevyfaervtsl及其制备方法和应用
CH716377B1 (it) * 2020-08-05 2020-12-30 Contrad Swiss Sa Idrogel ad applicazione topica efficace nel prevenire e/o attenuare la degenerazione della cartilagine.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
EP0495674A3 (en) * 1991-01-18 1993-09-01 Bristol-Myers Squibb Company Tgf-beta induced gene family
US5770209A (en) 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
US5408040A (en) 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5817310A (en) * 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
EP1217067A2 (en) 1994-07-12 2002-06-26 Human Genome Sciences, Inc. Connective tissue growth factor-2
CN1263852C (zh) * 1996-03-15 2006-07-12 穆尼恩公司 胞外基质信号分子
CA2249251A1 (en) 1996-03-20 1997-09-25 Human Genome Sciences, Inc. Human cytokine polypeptide

Also Published As

Publication number Publication date
DE69727558D1 (de) 2004-03-18
AU733382B2 (en) 2001-05-10
CN1263852C (zh) 2006-07-12
US6413735B1 (en) 2002-07-02
EP0888452A2 (en) 1999-01-07
US7064185B2 (en) 2006-06-20
CA2248549A1 (en) 1997-09-18
WO1997033995A3 (en) 1998-01-08
AU2329697A (en) 1997-10-01
US20020150986A1 (en) 2002-10-17
HK1018707A1 (en) 2000-01-04
JP4307552B2 (ja) 2009-08-05
ATE259419T1 (de) 2004-02-15
DE69727558T2 (de) 2004-12-16
CN1222193A (zh) 1999-07-07
WO1997033995A2 (en) 1997-09-18
EP0888452B1 (en) 2004-02-11
JP2000506732A (ja) 2000-06-06
US20060257965A1 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
DK0888452T3 (da) Human CYR61, et ekstracellulært matrix-signalmolekyle
IL195337A0 (en) Cyr61 compositions and methods
WO1998030694A3 (en) TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
PT93910A (pt) Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula
DE69638162D1 (de) Bindegewebs wachstumsfaktor (ctgf)
BR0315666A (pt) Dna de a34 e a33 do tipo 3, proteìnas, seus anticorpos e métodos de tratamento usando os mesmos
EP0686161A4 (en) ALPHA UNIT OF THE HUMAN BETA-2 INTEGRINS
DE69841140D1 (de) Interleukin-17 rezeptor-ähnliches protein
NZ510367A (en) Interleukin 17-like receptor protein nucleic acid sequence encoding the interleukin receptor protein and method of expressing protein in recombinant vector
BR9708518A (pt) Moduladores de fator associado a receptor tnf (traf) sua preparação e uso
ATE335818T1 (de) Ligand polypeptide für hypophyse g-protein gekoppeltes rezeptor-protein, deren herstellung und anwendung
BR9913942A (pt) Polinucleotìdeo e polipeptìdeo isolado, vetor de expressão, célula cultivada, constructo de dna codificador de uma proteìna de fusão, processos de produção de uma proteìna, de fusão de um polipeptìdeo e de um anticorpo para o polipeptìdeo e de detecção, em uma amostra de teste, da presença de um modulador da atividade da proteìna zalpha11 e de um ligante de receptor zalpha11 dentro de uma amostra de teste, e, anticorpo
WO2004039940A3 (en) Polynucleotide encoding novel human g-protein coupled receptors, and splice variants thereof
DE69737766D1 (de) Zusammensetzungen von stammzellfaktor (scf)-analogen und auf diese bezogene verfahren
ES2151557T3 (es) Corpusculos de proteinas de estaño, estanniocalcina.
ES2150937T3 (es) Autotaxina: proteina estimulante de la motilidad util en el diagnostico y terapia del cancer.
DE69831141D1 (de) Z2-19a, ein menschliches homolog von dem protein 2-19
EP1892250A3 (en) CYR61 compositions and methods
WO2000044898A3 (en) Novel agouti and agouti-related peptide analogs
DE60120507D1 (de) Menschliches leucinereiche wiederholungen enthaltendes protein, vorwiegend im dünndarm exprimiert, hlrrsi1
DE69631624D1 (de) Antikörper gegen menschliches restrictin
MX9708107A (es) Subunidad alfa de integrina beta 2 humana.
EP1712631A3 (en) Fc receptors and polypeptides